AlmarzaE., RioP., MezaN.W.et al.2007. Characteristics of lentiviral vectors harboring the proximal promoter of the vav proto-oncogene: A weak and efficient promoter for gene therapy. Mol. Ther., 15:1487–1494.
2.
AlmarzaE., ZhangF., SantilliG.et al.2011. Correction of SCID-X1 using an enhancerless Vav promoter. Hum. Gene Ther., 22:263–270.
DaveU.P., AkagiK., TripathiR.et al.2009. Murine leukemias with retroviral insertions at LMO2 are predictive of the leukemias induced in SCID-X1 patients following retroviral gene therapy. PLoS Genet., 5:e1000491.
5.
GehrkeS., JeromeV., MullerR.2003. Chimeric transcriptional control units for improved liver-specific transgene expression. Gene, 322:137–143.
6.
GinnS.L., LiaoS.H., DaneA.P.et al.2010. Lymphomagenesis in SCID-X1 mice following lentivirus-mediated phenotype correction independent of insertional mutagenesis and γc overexpression. Mol. Ther., 18:965–976.
HecklD., WickeD.C., BrugmanM.H.et al.2011. Lentiviral gene transfer regenerates hematopoietic stem cells in a mouse model for Mpl-deficient aplastic anemia. Blood(in press).
9.
JoynerA.L.1991. Gene targeting and gene trap screens using embryonic stem cells: New approaches to mammalian development. Bioessays, 13:649–656.
10.
ModlichU., NavarroS., ZychlinskiD.et al.2009. Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. Mol. Ther., 17:1919–1928.
11.
Moreno-CarranzaB., GentschM., SteinS.et al.2009. Transgene optimization significantly improves SIN vector titers, gp91phox expression and reconstitution of superoxide production in X-CGD cells. Gene Ther., 16:111–118.
12.
Pike-OverzetK., De RidderD., WeerkampF.et al.2007. Ectopic retroviral expression of LMO2, but not IL2Rγ, blocks human T-cell development from CD34+ cells: Implications for leukemogenesis in gene therapy. Leukemia, 21:754–763.
13.
SchambachA., GallaM., MaetzigT.et al.2007. Improving transcriptional termination of self-inactivating gamma-retroviral and lentiviral vectors. Mol. Ther., 15:1167–1173.
14.
ScobieL., HectorR.D., GrantL.et al.2009. A novel model of SCID-X1 reconstitution reveals predisposition to retrovirus-induced lymphoma but no evidence of γc gene oncogenicity. Mol. Ther., 17:1031–1038.
15.
SegalE., WidomJ.2009. From DNA sequence to transcriptional behaviour: A quantitative approach. Nat. Rev. Genet., 10:443–456.
16.
ThornhillS.I., SchambachA., HoweS.J.et al.2008. Self-inactivating gammaretroviral vectors for gene therapy of X-linked severe combined immunodeficiency. Mol. Ther., 16:590–598.
ZhangF., ThornhillS.I., HoweS.J.et al.2007. Lentiviral vectors containing an enhancer-less ubiquitously acting chromatin opening element (UCOE) provide highly reproducible and stable transgene expression in hematopoietic cells. Blood, 110:1448–1457.
19.
ZhouS., ModyD., DeravinS.S.et al.2010. A self-inactivating lentiviral vector for SCID-X1 gene therapy that does not activate LMO2 expression in human t cells. Blood, 116:900–908.
20.
ZuffereyR., DonelloJ.E., TronoD., HopeZ.J.1999. Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J. Virol., 73:2886–2892.
